Unknown PHASE4 INTERVENTIONAL 2-arm NCT01415063

Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

Sponsor: Sun Yat-sen University

Conditions Hepatocellular Carcinoma RFA TACE

Updated 4 times since 2017 Last updated: Aug 10, 2011 Started: Feb 28, 2011 Primary completion: Mar 31, 2013 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01415063, this PHASE4 trial focuses on Hepatocellular Carcinoma and RFA and remains ongoing. Sponsored by Sun Yat-sen University, it has been updated 4 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE4

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China